Aura Biosciences reports amended Schedule 13G/A showing Advent-affiliated entities may beneficially own an aggregate 3.258% of common stock, equal to 2,023,857 shares as of December 31, 2025.
Dr. Rajesh Parekh, a general partner of Advent, is reported with options to purchase 48,000 shares and may be deemed to beneficially own 2,071,857 shares (3.335%) as of December 31, 2025. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Positive
None.
Negative
None.
Insights
Filing clarifies ownership stakes and reporting attributions within an Advent affiliate group.
The amendment lists Advent Life Sciences LLP and multiple Advent funds as collectively holding 2,023,857 shares (3.258%) as of December 31, 2025, and identifies Dr. Rajesh Parekh with an aggregate economic interest of 2,071,857 shares including 48,000 option shares. The filing uses standard disclaimers to limit personal beneficial ownership claims.
This filing is a disclosure of ownership positions and allocation among affiliated reporting persons; subsequent Forms or confirmations would show any changes in voting or disposition. Filings with updated share counts or exercises will appear in later reports.
Amendment aligns reported percentages with affiliate aggregation and option holdings.
The Schedule 13G/A attributes shared voting and dispositive power of 2,023,857 shares to Advent and the Advent Funds, and reports Dr. Parekh's sole dispositive power for 48,000 option shares, producing an aggregate figure of 2,071,857 shares (3.335%) as of December 31, 2025. Signatures show the filing was executed by Dr. Parekh in his general partner capacity.
Disclosure preserves the reporting persons' disclaimer of beneficial ownership "except to the extent of any pecuniary interest therein," a typical compliance formulation; any future exercises or transfers would change the reported percentages and require new filings.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Aura Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
05153U107
(CUSIP Number)
02/13/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Advent Life Sciences LLP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,023,857.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,023,857.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,023,857.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.258 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Advent Life Sciences Fund I LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,023,857.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,023,857.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,023,857.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.258 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Rajesh Parekh, Ph.D.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,023,857.00
7
Sole Dispositive Power
48,000.00
8
Shared Dispositive Power
2,071,857.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,071,857.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.335 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Advent Life Sciences Fund III LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,023,857.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,023,857.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,023,857.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.258 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
ALS III Carry and Co-Invest LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,023,857.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,023,857.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,023,857.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.258 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
SCHEDULE 13G
CUSIP No.
05153U107
1
Names of Reporting Persons
Advent-Harrington Impact Fund LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,023,857.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,023,857.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,023,857.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.258 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: By virtue of the affiliate relationships among the Reporting Persons, as of December 31, 2025, each of Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. In addition, Dr. Parekh who is a general partner of Advent Life Sciences LLP and the other funds named herein, formerly served as a director of the Company, has options to purchase a total of 48,000 shares of Common Stock and may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aura Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
80 Guest Street, Boston, MASSACHUSETTS 2135
Item 2.
(a)
Name of person filing:
Advent Life Sciences LLP, Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, Advent-Harrington Impact Fund LP and Rajesh Parekh, Ph.D.
(b)
Address or principal business office or, if none, residence:
27 Fitzroy Square, London, United Kingdom W1T 6ES
(c)
Citizenship:
Citizenship: Advent Life Sciences LLP ("Advent") is a limited liability partnership organized under the laws of the United Kingdom. Advent Life Sciences Fund I LP, Advent Life Sciences Fund III LP, ALS III Carry and Co-Invest LP, and Advent-Harrington Impact Fund LP (collectively, the "Advent Funds") are limited partnerships organized under the laws of the United Kingdom. Dr. Parekh is a citizen of the United Kingdom.
(d)
Title of class of securities:
Common Stock, par value $0.00001 per share
(e)
CUSIP No.:
05153U107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of each of Advent and the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
(b)
Percent of class:
Advent Life Sciences LLP and the Advent Funds 3.258%; Dr. Parekh 3.335%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
By virtue of the relationships set forth herein, Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of Advent and each of the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
(iii) Sole power to dispose or to direct the disposition of:
Advent Life Sciences LLP and the Advent Funds 0% and Dr. Parekh 0.07727%,
(iv) Shared power to dispose or to direct the disposition of:
By virtue of the relationships set forth herein, Advent and the Advent Funds may be deemed to beneficially own in the aggregate 2,023,857 shares of Common Stock. Dr. Parekh who is a general partner of each of Advent and the Advent Funds, formerly served as a director of the Company and has options to purchase a total of 48,000 shares of Common Stock. By virtue of the relationships set forth herein, Dr. Parekh may be deemed to beneficially own in the aggregate 2,071,857 shares of Common Stock. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Advent Life Sciences LLP
Signature:
/s/Rajesh Parekh, Ph.D.
Name/Title:
General Partner of Advent Life Sciences LLP
Date:
02/13/2026
Advent Life Sciences Fund I LP
Signature:
/s/Rajesh Parekh, Ph.D.
Name/Title:
General Partner of Advent Life Sciences LLP
acting in its capacity as Manager of
Advent Life Sciences Fund I LP
Date:
02/13/2026
Rajesh Parekh, Ph.D.
Signature:
/s/Rajesh Parekh, Ph.D.
Name/Title:
/s/Rajesh Parekh, Ph.D.
Date:
02/13/2026
Advent Life Sciences Fund III LP
Signature:
/s/Rajesh Parekh, Ph.D.
Name/Title:
General Partner of Advent Life Sciences LLP
acting in its capacity as Manager of
Advent Life Sciences Fund III LP
Date:
02/13/2026
ALS III Carry and Co-Invest LP
Signature:
/s/Rajesh Parekh, Ph.D.
Name/Title:
General Partner of Advent Life Sciences LLP
acting in its capacity as Manager of ALS III Carry and Co-Invest LP
Date:
02/13/2026
Advent-Harrington Impact Fund LP
Signature:
/s/Rajesh Parekh, Ph.D.
Name/Title:
General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent-Harrington Impact Fund LP
Date:
02/13/2026
Comments accompanying signature: See comments re: reporting persons and signature information.
Exhibit Information
Agreement Regarding the Joint Filing of Schedule 13G dated February 11, 2022 (as filed by the Reporting Persons on Schedule 13G on February 14, 2022).
What stake does Advent Life Sciences hold in Aura Biosciences (AURA)?
Advent Life Sciences and affiliated Advent funds are reported to beneficially own 2,023,857 shares, representing 3.258% of common stock as of December 31, 2025. The filing aggregates holdings among the affiliated reporting persons.
How many Aura shares is Dr. Rajesh Parekh reported to beneficially own?
Dr. Parekh is reported with options to purchase 48,000 shares and may be deemed to beneficially own 2,071,857 shares, equal to 3.335% of common stock as of December 31, 2025
Does the filing state who has sole voting or dispositive power?
The filing reports 0 shares of sole voting power for Advent and the Advent Funds and 0 sole voting power for Dr. Parekh; shared voting and dispositive power of 2,023,857 shares is reported for the Advent group, with Dr. Parekh showing 48,000 sole dispositive shares via options.
Are the reported ownership percentages current to a specific date?
Yes. The percentages and share counts are stated as of December 31, 2025, per the filing's aggregation language and accompanying comments about affiliate relationships.
Did the reporting persons disclaim beneficial ownership?
Yes. Each reporting person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein, as stated verbatim in the filing's comment sections and Item 4 disclosures.
